Section 232 drug tariffs: the headline says 100%, the market risk is the messy transmission
The Opportunity
This is a policy-volatility short on a pharma proxy: a primary White House artefact (dated April 2, 2026) is cited in due diligence as the anchor for a Section 232 tariff regime on patented pharmaceuticals and ingredients, with the rest of the ecosystem still digesting implementation and exemptions. 7A stays SHORT because the first-order effect is uncertainty and potential cost/price transmission risk, and the second-order effect is that winners and losers are determined by exemptions and negotiated deals that are not evenly distributed across the sector.
The Timing
Freshness is 88 with oldest claim date tagged to 2026-04-02, so the window is about how quickly analysts produce a definitive covered-company list and an exemption map, not whether the policy exists. The regime is Mixed 58, which can mask sector-specific repricing because tape rotation can dominate day-to-day moves; that is exactly why the proxy expression is used. Confirmation tripwires are the release of annexes, lists, or explicit guidance that narrows coverage; contradiction tripwires are clear carve-outs that materially limit the effective rate for the largest importers.
The Evidence
The due diligence explicitly anchors to a White House publication ( whitehouse.gov ). The hydrated evidence cluster contains secondary summaries and adjacent CMS process items rather than a single consolidated implementation explainer, including a tariff-cost narrative piece with an effective-date claim ( getoutofdebt.org ) and a CMS prior authorisation proposed rule that speaks to broader payer friction in parallel ( natlawreview.com ).